Chemical stabilities and biological activities of thalidomide and its N-aikyl analogs

Pharmaceutical Research

Volumn 19, Issue 8, 2002, Pages 1232-1235

  Goosen, Colleen ^a   Laing, Timothy J ^a   Du Plessis, Jeanetta ^a   Goosen, Theunis C ^a   Rao, Tharaknath B ^a   Flynn, Gordon L ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Biological activity; Chemical stability; Half life; N alkyl analogs; Thalidomide; Tumor necrosis factor alpha

Indexed keywords

BUFFER; LIPOPOLYSACCHARIDE; N METHYLTHALIDOMIDE; N PENTYLTHALIDOMIDE; N PROPYLTHALIDOMIDE; PHOSPHATE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; CALCULATION; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG HALF LIFE; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; MONONUCLEAR CELL; NORMAL HUMAN; PERIPHERAL CIRCULATION; PH; PRIORITY JOURNAL; PROTEIN DETERMINATION; TEMPERATURE SENSITIVITY;

DRUG STABILITY; HUMANS; LEUKOCYTES, MONONUCLEAR; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036692384     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1019866730266     Document Type: Article

References (17)

1. The saga of thalidomide
2. Thalidomide in the treatment of lepra reactions
3. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
4. Thalidomide, a potent agent for the treatment of graft-versus-host-disease
5. Thalidomide: Use and possible mode of action in reactional lepromatous leprosy and in various other conditions
6. Thalidomide as treatment of refractory aphthous ulceration related to human-immunodeficiency-virus infection
7. Thalidomide, a promising new treatment for rheumatoid arthritis
8. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes
9. Thalidomide exerts its inhibition action on tumor necrosis factor α by enhancing mRNA degradation
10. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) vs. placebo in rheumatoid arthritis
11. TNF-α in rheumatoid arthritis and prospects of anti-TNF therapy
12. Thalidomide: A pharmaceutical enigma
13. Percutaneous delivery of thalidomide and its N-alkyl analogs
14. Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs
15. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity
16. The metabolism of thalidomide: The spontaneous hydrolysis of thalidomide in solution
17. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-α by mononuclear cells